The proprietary diagnostic platform technology allows the detection and monitoring of unique biomarkers associated with regulatory chromosomal conformation signatures representing the deregulation of the key genes implicated in onset, progression or amelioration of a disease.
Licensing the technology offers access to a high-throughput process for analysis and validation of biomarkers for monitoring of systemic changes, supported by epigenetic mechanisms of deregulation. The EpiSwitchTM test has been highly standardised and is of Industry Standard quality.
The epigenetic nature and biochemical properties of the chromosomal signature targets offer a uniquely informative read-out at a low cost and with a significant reduction in assessment time.
